Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain...( TEL AVIV Israel July 14 /- Elbit ...),Health

TEL AVIV, Israel, July 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. (TASE: EMIT, Nasdaq: EMITF), announced today that, its subsidiary (in which EI holds indirectly approximately 58.34%, InSightec Ltd., announced today that a team at the University Children's Hospital Zurich has completed a feasibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (TcMRgFUS) for the treatment of neuropathic pain. Ten adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brain ablation surgery (central lateral thalamotomy) with transcranial TcMRgFUS and showed improvement in pain scores and reduction of pain medication with no adverse effects at three months follow-up. This is the first study in the world to test non-invasive transcranial focused ultrasound as a treatment modality for functional brain disorders.

"The Neuropathic pain study performed at Zurich demonstrated the feasibility to treat these patients non-invasively without adverse events and with very favorable preliminary efficacy" said Dr. Kobi Vortman, President and CEO of InSightec.

"The results of this study set the ground for extensive brain study addressing the areas of functional diseases like Parkinson and Epilepsy, brain tumors and stroke. This technology has the potential to help significant amount of patients while reducing trauma and morbidity. To advance this study InSightec is collaborating with leading neurosurgery and neurology institutes around the world."

Shimon Yitzhaki, Elbit Imaging's President and CEO, commented:

InSightec's outstanding breakthrough technology in the transcranial field has without doubt placed InSightec on the map as being the world's leading developer in the field of non-invasive treatment using MR-guided focused u
'/>"/>